Biotech Values

[biomaven0]

they can coformulate Fovista&Lucentis

I wonder if that would raise the FTC's hackles? Certainly REGN would complain bitterly about such a merger and resulting co-formulation. It speaks to so-called "tying" where a company attempts to extend a dominant position in one product so as to also encompass other products. I'm not aware of any examples of this happening in pharmaceuticals.

Peter